Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ESMO open

Showing results (71-80 of 2,241) with videos related to

Pageof 225
Sort By:
ESMO Open|June 18, 2020
Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytomaLauriane Eberst, Philippe A Cassier, Mehdi Brahmi, et al.
ESMO Open|April 22, 2020
Announcing the <i>ESMO Open</i> special issue on upcoming molecular targets for cancer treatmentGilberto Morgan, Matthias Preusser, Christoph Zielinski
ESMO Open|April 22, 2020
Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancerRhode Bijlsma, Roel Wouters, Hester Wessels, et al.
ESMO Open|April 10, 2020
New emerging targets in cancer immunotherapy: the role of neoantigensLeticia De Mattos-Arruda, Juan Blanco-Heredia, Carmen Aguilar-Gurrieri, et al.
ESMO Open|September 12, 2021
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
ESMO Open|September 4, 2025
Letter Re: 'Development of a risk score based on clinical-pathological features to predict the presence of germline BRCA1/2 pathogenic variants in ovarian cancer patients'S Liu, X Wu
ESMO Open|September 4, 2025
Reply letter to comments on: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Pietrantonio
ESMO Open|September 4, 2025
Explainable machine learning models based on clinical trial surrogate outcomes for predicting overall survival in head and neck cancersW Hwang, H A Jung, L J Worth, et al.
ESMO Open|September 4, 2025
The rising tides of cancers among young adultsF André, E Rassy, B Achutti-Duso, et al.
ESMO Open|September 5, 2025
Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in ChinaG Wang, J Qin, W Nong, et al.
Pageof 225

Showing results (71-80 of 2,241) with videos related to

Sort By:
Pageof 225
ESMO Open|June 18, 2020
Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytomaLauriane Eberst, Philippe A Cassier, Mehdi Brahmi, et al.
ESMO Open|April 22, 2020
Announcing the <i>ESMO Open</i> special issue on upcoming molecular targets for cancer treatmentGilberto Morgan, Matthias Preusser, Christoph Zielinski
ESMO Open|April 22, 2020
Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancerRhode Bijlsma, Roel Wouters, Hester Wessels, et al.
ESMO Open|April 10, 2020
New emerging targets in cancer immunotherapy: the role of neoantigensLeticia De Mattos-Arruda, Juan Blanco-Heredia, Carmen Aguilar-Gurrieri, et al.
ESMO Open|September 12, 2021
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
ESMO Open|September 4, 2025
Letter Re: 'Development of a risk score based on clinical-pathological features to predict the presence of germline BRCA1/2 pathogenic variants in ovarian cancer patients'S Liu, X Wu
ESMO Open|September 4, 2025
Reply letter to comments on: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Pietrantonio
ESMO Open|September 4, 2025
Explainable machine learning models based on clinical trial surrogate outcomes for predicting overall survival in head and neck cancersW Hwang, H A Jung, L J Worth, et al.
ESMO Open|September 4, 2025
The rising tides of cancers among young adultsF André, E Rassy, B Achutti-Duso, et al.
ESMO Open|September 5, 2025
Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in ChinaG Wang, J Qin, W Nong, et al.
Pageof 225